Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT07602517
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Inflammatory Bowel Diseases
  • Spondyloarthritis

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Guselkumab — DRUG
    Guselkumab intravenous or subcutaneous induction.

Study Details

This is an observational study of a prospective cohort of guselkumab-initiating Crohn's Disease (CD) and Ulcerative Colitis (UC) patients to identify new or incident spondyloarthritis. This study will include adult patients aged 18-75 with IBD who are undergoing guselkumab intravenous or subcutaneous induction over a 1-year timeframe.

Key Dates

Start date
May 20, 2026
Status verified
May 2026
Primary completion
May 20, 2028
Completion
May 20, 2029

Study Design

Enrollment
75 participants (estimated)

Arms

  • Arm: IBD Patients Initiating Guselkumab
    Individuals with confirmed clinical SpA diagnosis who are initiating guselkumab as standard care for CD or UC will take surveys every 3 months over a 1-year timeframe.

Primary Outcome Measure

Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score [ Time Frame: Baseline, Month 6 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By research site
NYU Langone Health· New York, NY

Related Studies